GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Interest Expense

EV Biologics (EV Biologics) Interest Expense : $-0.99 Mil (TTM As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. EV Biologics's interest expense for the three months ended in Dec. 2017 was $ -0.99 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2017 was $-0.99 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. EV Biologics's Operating Income for the three months ended in Dec. 2017 was $ 4.87 Mil. EV Biologics's Interest Expense for the three months ended in Dec. 2017 was $ -0.99 Mil. EV Biologics's Interest Coverage for the quarter that ended in Dec. 2017 was 4.93. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


EV Biologics Interest Expense Historical Data

The historical data trend for EV Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Interest Expense Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Interest Expense
-1.15 -1.18 -1.30 -1.03 -0.66

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.20 -1.04 - -0.99

EV Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

EV Biologics's Interest Expense for the three months ended in Dec. 2017 was $-0.99 Mil. Its Operating Income for the three months ended in Dec. 2017 was $4.87 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2017 was $0.00 Mil.

EV Biologics's Interest Coverage for the quarter that ended in Dec. 2017 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2017 )/Interest Expense (Q: Dec. 2017 )
=-1*4.871/-0.988
=4.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

By ACCESSWIRE ACCESSWIRE 08-12-2021

EV Biologics Updates on NFT Dividend

By ACCESSWIRE ACCESSWIRE 11-12-2021

EV Biologics NFT Dividend Information

By ACCESSWIRE ACCESSWIRE 08-09-2021

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 05-17-2022

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021